Home Newsfeeds Raymond James Downgrades DCP Midstream to Market Perform

Raymond James Downgrades DCP Midstream to Market Perform

Raymond James analyst Justin Jenkins downgrades DCP Midstream (NYSE:DCP) from Strong Buy to Market Perform.

byBenzinga Newsdesk

January 9, 2023

1 minute read

Raymond James analyst Justin Jenkins downgrades DCP Midstream (NYSE:DCP) from Strong Buy to Market Perform.

News

SpartanNash, Shipt Announce Expansion Of Same-Day Delivery Partnership

By Benzinga Newsdesk

November 1, 8:37 AM

Food solutions company SpartanNash (the "Company") (NASDAQ:SPTN) today announced its growing partnership with same-day delivery service Shipt. Shipt users will now be able to shop nearly 90

SPTN

Atara Biotherapeutics Presents New MRI And Updated Open-Label Extension Data From Phase 1 Study Of ATA188 In Progressive Multiple Sclerosis At ECTRIMS 2022 October 26-28

By Benzinga Newsdesk

October 26, 2:07 AM

Sustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up Patients Treated with ATA188 that Achieved CDI

ATRA

French Aerospace Firm Safran Bags $1.2B Worth Contracts From Emirates

By Shivani Kumaresan

November 14, 2:37 PM

French aerospace and defense company Safran (OTC: SAFRY) has bagged several contracts worth over $1.2 billion combined from Emirates.

Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders

By Vandana Singh

December 13, 10:51 AM

Wave Life Sciences Ltd (NASDAQ:WVE) and GSK plc (NYSE:GSK) have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing…

GSK

Raymond James Downgrades DCP Midstream to Market Perform

Related Posts

SpartanNash, Shipt Announce Expansion Of Same-Day Delivery Partnership

Atara Biotherapeutics Presents New MRI And Updated Open-Label Extension Data From Phase 1 Study Of ATA188 In Progressive Multiple Sclerosis At ECTRIMS 2022 October 26-28

French Aerospace Firm Safran Bags $1.2B Worth Contracts From Emirates

Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders